ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration

Stock Information for abrdn Life Sciences Investors Shares of Beneficial Interest

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About abrdn Life Sciences Investors Shares of Beneficial Interest

ProQR to Participate in 8th Annual Evercore Healthcare Conference
ProQR Announces Third Quarter 2025 Operating and Financial Results
ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025
ProQR to Participate in Upcoming Investor Conferences in October 2025
ProQR Announces Second Quarter 2025 Operating and Financial Results
ProQR Announces Upcoming Presentation at RNA Editing Summit
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.